EFFECTOR THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.89 USD | +4.42% |
|
+11.18% | -83.83% |
| Apr. 04 | Health Care Down on Retreat From Risk -- Health Care Roundup | DJ |
| Apr. 04 | Top Midday Decliners | MT |
Presenter SpeechBenjamin Burnett (Analysts)Okay. All right. Well, let's get started. Welcome, ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Companyâs lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.89
USD
Average target price
11
USD
Spread / Average Target
+482.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -83.83% | 6.97M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- EFTR Stock
- News eFFECTOR Therapeutics, Inc.
- Transcript : EFFECTOR Therapeutics, Inc. - Special Call
